ELOX Stock — Eloxx Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$17.45

Market cap

$70.4M

Cash

$62.0M

Enterprise value

$8.4M

Balance sheet

Cash	$62.0M
Debt	$0.0M
Net cash	$62.0M
Enterprise value	$8.4M
Basic shares	4.0M shares
Fully diluted shares	13.2M shares
Fully diluted market cap	$230.7M
Cash per share	$15.49

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ELOX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 11 - Sep 22	Exaluren	Phase 2	Alport Syndrome, X-Linked; Alport Syndrome, Autosomal Recessive	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

exaluren

Phase 2 · Active Modality: small molecule (oral/injectable; ribosome modulator)

Target premature termination codons (nonsense mutations)

Partnerships n/a; licensed from TRDF (up to $6.5M milestones per product, low-to-mid single-digit royalties); CFF funding obligations reduced to <1% of net sales

Indications

Alport syndrome with nonsense mutations (NMAS) (Phase 2)
Autosomal dominant polycystic kidney disease with nonsense mutations (nmADPKD) (Preclinical)

Catalysts

— Q3 2026
— mid-2027
— end of 2027
— 2027
— mid-2028

Status note Lead candidate; completed Phase 2a (n=3) in NMAS. Prior Phase 2 studies in CF and nephropathic cystinosis also completed; program focus shifted to kidney indications. Orphan designations: FDA (Alport syndrome), EU (ADPKD, Jul 2026).

ZKN-013

Phase 1 · Active Modality: small molecule (oral ribosome modulating agent)

Target premature termination codons (nonsense mutations)

Partnerships Almirall, S.A.: exclusive global license (Mar 2024); $3M upfront + $3M development milestone received 2024; up to ~$470M additional milestones; tiered royalties. Almirall responsible for development/commercialization.

Indications

Recessive dystrophic epidermolysis bullosa (RDEB) with nonsense mutations (Phase 1)
Junctional epidermolysis bullosa (JEB) with nonsense mutations (Phase 1)

Status note Partnered program; Almirall conducting Phase 1 in healthy volunteers. Rights revert to Eloxx if Almirall terminates for convenience.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Exaluren
Lead indication	Alport Syndrome, X-Linked
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07523581	Phase 2	Recruiting	Sponsor	ELOX	—	Alport Syndrome, X-Linked; Alport Syndrome, Autosomal Recessive	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Eloxx Pharmaceuticals, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ELOX — Eloxx Pharmaceuticals Inc.